JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Scope & Guideline

Elevating discourse in cardiovascular medicine.

Introduction

Welcome to the JOURNAL OF THROMBOSIS AND THROMBOLYSIS information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of JOURNAL OF THROMBOSIS AND THROMBOLYSIS, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0929-5305
PublisherSPRINGER
Support Open AccessNo
CountryNetherlands
TypeJournal
Convergefrom 1994 to 2024
AbbreviationJ THROMB THROMBOLYS / J. Thromb. Thrombolysis
Frequency8 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressVAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS

Aims and Scopes

The Journal of Thrombosis and Thrombolysis aims to advance the understanding of thrombotic and thrombolytic processes, focusing on the mechanisms, diagnosis, treatment, and prevention of thromboembolic diseases. It encompasses a wide range of topics related to coagulation, anticoagulation therapies, and the impact of various conditions on thrombotic events.
  1. Thromboembolic Disease Research:
    The journal emphasizes research on various forms of thromboembolic diseases, including venous thromboembolism (VTE), pulmonary embolism, and arterial thrombosis, investigating their epidemiology, risk factors, and clinical outcomes.
  2. Anticoagulation Therapy:
    It publishes studies on the efficacy and safety of anticoagulation therapies, including direct oral anticoagulants (DOACs), vitamin K antagonists, and novel anticoagulants, focusing on their use in different patient populations.
  3. Mechanisms of Coagulation and Thrombosis:
    Research exploring the underlying biological mechanisms of coagulation, the role of platelets, and the genetic factors influencing thrombotic events is a core focus, contributing to the understanding of thrombosis at a molecular level.
  4. Clinical Guidelines and Practice:
    The journal provides a platform for the dissemination of clinical guidelines and best practices in the management of thromboembolic diseases, integrating evidence-based medicine into clinical practice.
  5. Innovative Diagnostic Approaches:
    It highlights advancements in diagnostic methodologies for thromboembolic diseases, including imaging techniques and biomarkers, facilitating early detection and management.
Recent years have seen the emergence of several key themes within the Journal of Thrombosis and Thrombolysis, reflecting the evolving landscape in thrombosis research and clinical practice.
  1. COVID-19 Related Thrombosis:
    A significant increase in studies addressing thrombotic complications associated with COVID-19 has emerged, highlighting the pandemic's impact on thromboembolic disease research and management.
  2. Machine Learning and Predictive Analytics:
    There is a growing trend towards utilizing machine learning and predictive analytics in identifying thrombosis risk factors and outcomes, representing a shift towards data-driven approaches in clinical research.
  3. Personalized Anticoagulation Strategies:
    Emerging research focuses on individualized anticoagulation therapy, considering genetic, demographic, and clinical variables to optimize treatment outcomes for patients.
  4. Cancer-Associated Thrombosis:
    An increasing number of studies are dedicated to understanding the mechanisms and management of thrombosis in cancer patients, reflecting the critical interplay between malignancy and thromboembolic risk.
  5. Longitudinal Studies and Real-World Evidence:
    There is a trend towards conducting longitudinal and real-world studies to assess the long-term outcomes of various thromboembolic treatments, emphasizing the importance of practical evidence in clinical decision-making.

Declining or Waning

While the journal continues to cover a wide array of topics, some previously prominent areas of focus appear to be declining in frequency or interest, reflecting changes in the clinical landscape and research priorities.
  1. Traditional Antithrombotic Therapies:
    Research on older antithrombotic agents like unfractionated heparin and warfarin is becoming less common as newer therapies gain prominence, leading to a shift in focus towards novel anticoagulants and their comparative effectiveness.
  2. Generalized Risk Factors for Thrombosis:
    While risk factors for thrombosis were once a major focus, there is a noticeable decline in studies addressing generalized risk factors, as researchers are now more focused on specific patient populations and their unique risk profiles.
  3. Non-Pharmacological Interventions:
    Research on non-pharmacological interventions for thrombosis prevention, such as lifestyle modifications or physical therapies, is less frequently published, likely overshadowed by pharmacological advancements.
  4. Thrombolysis Techniques:
    The frequency of studies on traditional thrombolytic techniques appears to be waning, as interest shifts towards more innovative approaches and technologies in thrombectomy and catheter-directed therapies.

Similar Journals

BLOOD COAGULATION & FIBRINOLYSIS

Connecting Researchers to the Future of Blood Science
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0957-5235Frequency: 8 issues/year

BLOOD COAGULATION & FIBRINOLYSIS, a distinguished journal in the field of hematology, is published by Lippincott Williams & Wilkins, a reputable name in academic publishing. Since its inception in 1990, this journal has been committed to advancing the understanding of blood coagulation and fibrinolysis, focusing on the molecular mechanisms, clinical implications, and therapeutic aspects of these critical processes. With an impact factor reflecting its significance within the academic community, currently ranking Q3 in both Hematology and Miscellaneous Medicine for 2023, this journal serves as a pivotal platform for researchers and professionals alike. By providing access to cutting-edge research and reviews, BLOOD COAGULATION & FIBRINOLYSIS endeavors to foster collaboration and innovation in the treatment of coagulation disorders. Interested readers can explore ongoing contributions to the field through subscriptions and institutional access options.

THROMBOSIS RESEARCH

Elevating Hematology Through Rigorous Research
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0049-3848Frequency: 12 issues/year

THROMBOSIS RESEARCH is a leading peer-reviewed journal in the field of hematology, published by PERGAMON-ELSEVIER SCIENCE LTD. With an impressive impact factor and ranked within the top 10 of 137 in its category according to Scopus, this journal provides a critical platform for the dissemination of innovative research related to thrombosis and hemostasis. Established in 1972, THROMBOSIS RESEARCH has been at the forefront of scholarly communication, addressing key issues, findings, and advancements over more than five decades. Recognized for its high-quality content, the journal is categorized in the Q1 quartile for 2023, reflecting its influence and relevance within the scientific community. Researchers, medical professionals, and students engaged in the study of blood disorders will find valuable insights and the latest discoveries within its pages. Although currently not an open-access publication, THROMBOSIS RESEARCH remains accessible to a wide audience through institutional subscriptions, ensuring that vital research continues to inform and enhance clinical practices around the globe.

Annals of Vascular Diseases

Pioneering Insights in Vascular Health
Publisher: ANNALS VASCULAR DISEASES EDITORIAL OFFICEISSN: 1881-641XFrequency: 4 issues/year

Annals of Vascular Diseases is a leading international journal dedicated to the comprehensive exploration of vascular pathology, aimed at advancing knowledge in the field through innovative research and insightful reviews. Published by the ANNALS VASCULAR DISEASES EDITORIAL OFFICE and available in both print (ISSN: 1881-641X) and electronic format (E-ISSN: 1881-6428), this journal has embraced Open Access since 2017, facilitating wider dissemination and accessibility of vital research findings. With its focus on clinical and experimental studies relating to vascular diseases, the journal serves as a crucial platform for researchers, medical professionals, and students who seek to stay at the forefront of clinical advancements. By fostering collaboration and sharing knowledge, Annals of Vascular Diseases plays a significant role in shaping the future of vascular research and treatment strategies worldwide.

Lung India

Pioneering the future of respiratory research.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0970-2113Frequency: 6 issues/year

Lung India is a premier open-access journal dedicated to the dissemination of high-quality research in the field of Pulmonary and Respiratory Medicine. Published by Wolters Kluwer Medknow Publications, it has been forging a path in respiratory healthcare since its inception in 2004. With its impactful contributions to clinical practice and research, Lung India holds a solid position in the academic landscape, evidenced by its ranking in the Q3 quartile for Pulmonary and Respiratory Medicine as of 2023, and its Scopus rank of #99 out of 155. The journal is particularly important for researchers, clinicians, and students in India and beyond, providing a platform for the latest findings and developments in respiratory care, lung disease management, and innovative treatment methods. With a commitment to accessibility, Lung India aims to promote knowledge sharing among professionals and support the advancement of respiratory health. The journal is well-equipped to cater to a diverse audience, ensuring that vital research is readily accessible and impactful.

Journal of Atherosclerosis and Thrombosis

Elevating the standards of cardiovascular research and discovery.
Publisher: JAPAN ATHEROSCLEROSIS SOCISSN: 1340-3478Frequency: 12 issues/year

Journal of Atherosclerosis and Thrombosis is a leading academic publication dedicated to advancing research in the fields of cardiovascular medicine, biochemistry, and internal medicine. Published by the Japan Atherosclerosis Society, this esteemed journal operates from its headquarters in Tokyo, Japan, and has been a vital resource in its area since its inception in 1994. With its robust impact in Cardiology and Cardiovascular Medicine, ranking in the top quartile (Q1) as of 2023, and a commendable standing in Internal Medicine and Biochemistry, the journal fosters an environment of innovation and discovery, showcasing significant studies and advancements that shape clinical practices and therapeutic approaches. Though not an open-access publication, it offers a wealth of insights to researchers, professionals, and students seeking to deepen their understanding of atherosclerosis and thrombosis. By continually featuring high-quality articles, the Journal of Atherosclerosis and Thrombosis plays an essential role in bridging the gap between research and practice, facilitating critical conversations that influence the future of cardiovascular health.

Research and Practice in Thrombosis and Haemostasis

Elevating clinical practice through shared research.
Publisher: ELSEVIERISSN: Frequency: 8 issues/year

Research and Practice in Thrombosis and Haemostasis, published by Elsevier, is a prominent open-access journal dedicated to advancing the field of hematology through high-quality research and clinical practice. Since its inception in 2017, this journal has established itself as a vital resource for researchers, healthcare professionals, and students interested in thrombosis and hemorrhage management, showcasing original research, reviews, and clinical studies. The journal’s commitment to accessible knowledge is reflected in its open-access model, allowing researchers worldwide to share their findings without financial barriers. With an impressive 2023 Scopus rank of #42 out of 137 in the hematology category and a respectable Q2 classification, it provides an authoritative platform for innovative ideas and cutting-edge developments in the field. As the journal continues to grow in stature, it aims to foster collaboration and knowledge exchange amongst professionals dedicated to improving patient outcomes in thrombosis and hemostasis.

Thrombosis Journal

Pioneering open-access discoveries in thrombosis.
Publisher: BMCISSN: 1477-9560Frequency: 1 issue/year

Thrombosis Journal is a pioneering open-access publication offering critical insights into the field of hematology, contributing significantly to the understanding of thrombotic diseases. Published by BMC since its inception in 2003, this journal stands out with its commitment to accessibility and dissemination of research, ensuring that valuable findings are readily available to the global scientific community. With an impressive Q2 ranking in the Hematology category as of 2023, the journal boasts a notable presence in the Scopus rankings, positioned at Rank #73/137 in its field. Researchers, healthcare professionals, and students can benefit from a rich array of articles that encompass clinical studies, reviews, and innovative methodologies, all aimed at advancing knowledge and fostering collaboration in the field. The journal is headquartered in the United Kingdom, and its open-access model has enabled a diversity of perspectives and research innovations to flourish, solidifying Thrombosis Journal as an essential resource for those dedicated to combating thrombotic disorders.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Pioneering insights into thrombosis and vascular disorders.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1079-5642Frequency: 12 issues/year

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, published by Lippincott Williams & Wilkins, is a leading journal in the field of cardiovascular medicine, dedicated to the advancement of research surrounding arterial diseases, thrombosis, and vascular biology. With an impressive impact factor indicative of its reach and influence, this journal occupies a prominent position in the Q1 category of cardiology, ranking 13th out of 387 in its field according to Scopus, placing it within the top 96th percentile among cardiovascular research journals. Since its inception in 1990, ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY has been pivotal in disseminating cutting-edge research that drives innovation and education in cardiovascular health. Although it does not operate under an open access model, the journal is a vital resource for researchers, clinicians, and students looking for high-quality, peer-reviewed articles that contribute to the understanding and treatment of cardiovascular and vascular disorders. Its commitment to rigorous scientific standards and its focus on impactful findings make it an essential publication for anyone dedicated to the field.

PHLEBOLOGY

Exploring the future of phlebology and cardiovascular care.
Publisher: SAGE PUBLICATIONS INCISSN: 0268-3555Frequency: 8 issues/year

PHLEBOLOGY is a renowned academic journal published by SAGE Publications Inc. that focuses on the evolving field of phlebology and related cardiovascular issues. With an ISSN of 0268-3555 and an E-ISSN of 1758-1125, this journal serves as a pivotal platform for disseminating high-quality research, clinical findings, and innovative practices in venous disease management and treatment. Operating from the United Kingdom, tasked with a mission to advance the scientific understanding and clinical practice surrounding venous disorders, PHLEBOLOGY is currently ranked in the Q3 category for both Cardiology and Cardiovascular Medicine, as well as in Medicine (miscellaneous) for 2023. Its Scopus rank of #192 out of 387 highlights its commitment to excellence, ensuring that it reaches a respectable 50th percentile within its fields. Although it does not offer open access, the journal invites contributions from researchers, healthcare professionals, and students, fostering a community dedicated to improving patient outcomes and promoting evidence-based practices in venous health.

Hamostaseologie

Leading the Way in Hematology: Uncovering the Science of Coagulation
Publisher: GEORG THIEME VERLAG KGISSN: 0720-9355Frequency: 4 issues/year

Hamostaseologie is a prominent academic journal dedicated to the field of hematology, published by GEORG THIEME VERLAG KG. With an ISSN of 0720-9355 and an E-ISSN of 2567-5761, this journal has been at the forefront of critical research and advancements since its inception in 1981, and it continues to maintain its relevance in the scientific community with a converged publication until 2024. Ranked in the Q3 quartile in Hematology for 2023, and positioned at #44 out of 137 in the Scopus Medicine Hematology category, it represents a substantial contribution to scholarly discourse. Researchers and professionals alike will find valuable insights within its pages, as it disseminates rigorous studies and reviews that address pertinent issues related to hemostasis and coagulation. While the journal does not currently offer Open Access, readers can access its valuable content through institutional subscriptions, making it an essential resource for students, clinicians, and researchers aiming to deepen their understanding of hematological science.